Patents Issued in May 12, 2016
-
Publication number: 20160129110Abstract: Immunoprotective primary mesenchymal stems cells (IP-MSC) which episomally express multiple immunoreactive polypeptides that specifically target a pathogen (e.g., an infectious species of virus, bacterium, or parasite) or toxin are described herein. The IP-MSC express two or more (e.g., 2 to about 100) immunoreactive polypeptides (e.g., full antibodies, single-chain antibodies (ScFV), Fab or F(ab)2 antibody fragments, diabodies, tribodies, and the like), and optionally one or more other immunomodulating polypeptides, e.g., a cytokine such as an interleukin (e.g., IL-2, IL-4, IL-6, IL-7, IL-9, and IL-12), an interferon (e.g., IFN?, IFN?, or IFN?), and the like, which can enhance the effectiveness of the immunoreactive polypeptides.Type: ApplicationFiled: July 17, 2015Publication date: May 12, 2016Applicants: AUTOIMMUNE TECHNOLOGIES, LLC, THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUNDInventors: Robert Francis GARRY, Luis Manuel BRANCO, Bruce Alan BUNNELL, Russell B. WILSON, Samuel E. HOPKINS
-
Publication number: 20160129111Abstract: Described herein are methods for delivering an anti-cancer agent to a tumor in a subject. The method involves administering to the subject (i) gold particles and (ii) at least one-anti-cancer agent directly or indirectly bonded to the macromolecule and/or unbound to the macromolecule; and exposing the tumor to light for a sufficient time and wavelength in order for the gold particles to achieve surface plasmon resonance and heating the tumor.Type: ApplicationFiled: January 15, 2016Publication date: May 12, 2016Applicant: UNIVERSITY OF UTAH RESEARCH FOUNDATIONInventors: Hamid GHANDEHARI, Adam GORMLEY, Abhijit RAY, Nate LARSON
-
Publication number: 20160129112Abstract: Described herein are therapeutic compositions comprising a therapeutic agent and pyrophosphate.Type: ApplicationFiled: May 27, 2014Publication date: May 12, 2016Inventor: Kelly NEELON
-
Publication number: 20160129113Abstract: The present invention is directed to a tablet comprising at least one bitter tasting and/or mucosa numbness causing pharmaceutically active compound; and at least one zinc salt. In addition, the present invention relates to the use of a zinc salt to reduce or mask the bitter taste of or the numbness of the mucosa caused by pharmaceutically active compounds.Type: ApplicationFiled: December 14, 2015Publication date: May 12, 2016Inventor: Klaus STORM
-
Publication number: 20160129114Abstract: A liquid composition comprising (a) 21 to 70 parts by weight of a solvent having no nitrogen atom and having a carbonyl or sulfonyl group in the molecule, (b) 30 to 78.9 parts by weight of at least one component selected from the group consisting of a non-cyclic alcohol, an alkylene glycol, a polyalkylene glycol, a triol, a glycol monoacetate and a glycol monoalkyl ether, (c) 0.001 to 30 parts by weight of a physiologically active ingredient, and (d) 0.001 to 49 parts by weight of water.Type: ApplicationFiled: January 15, 2016Publication date: May 12, 2016Inventors: Hiroshi DAIRIKI, Rieko NAKAMURA
-
Publication number: 20160129115Abstract: In one aspect, the invention provides liquid stable formulations of antithrombin.Type: ApplicationFiled: June 19, 2015Publication date: May 12, 2016Applicant: LFB USA, Inc.Inventors: Gerald R. Magneson, Greg J. Allard, Nicholas C. Masiello, Usha S. Patel, Lauren K. Fontana, Joseph L. Pearce, Jerry A. Grandoni
-
Publication number: 20160129116Abstract: A formulation and method for delivery of bioactive substances when applied to, or within, the skin or other exterior region of a mammal. for example, a patient, includes a vasoactive agent; an osmolyte; and an active ingredient. The formulation is sufficiently hygroscopic so as to create a condition of hypertonicity when absorbed by the skin. When the formulation is applied to the skin, the vasoactive agent can be delivered to the dermis so as to contact the vasculature of a patient.Type: ApplicationFiled: December 28, 2015Publication date: May 12, 2016Inventors: Stephen G. Carter, Zhen Zhu, Kanu Patel, John J. Masiz
-
Publication number: 20160129117Abstract: The purpose of the present invention is to avoid side effects from contained medicines. Provided are: a preparation obtained by mixing a boronic acid compound and a block copolymer represented by general formula (I); and a production method therefor.Type: ApplicationFiled: June 27, 2014Publication date: May 12, 2016Inventors: Masatoshi Abe, Masaharu Nakamura, Osamu Miyazaki, Keiko Sekine
-
Publication number: 20160129118Abstract: This invention relates to a cohesive thin liquid bolus comprising an aqueous solution of at least one food grade biopolymer and at least one bioactive compound, to the use of said cohesive thin liquid bolus for promoting safer swallowing of food boluses in dysphagic patients and to a method for preparing the bolus.Type: ApplicationFiled: June 4, 2014Publication date: May 12, 2016Inventors: Robert Redgwell, Adam Burbidge, Jan Engmann, Simina Popa Nita, Jane Durga
-
Publication number: 20160129119Abstract: An object is to provide dispersion containing lipid peptide type compound useful as low molecular weight gelator, such as lipid dipeptide and lipid tripeptide, and dissolution accelerator capable of dissolving the lipid peptide type compound at lower temperature and more easily. It is also an object to provide dispersion that can form hydrogel by simpler method and under milder condition (low temperature) and from which gel can be obtained as gel having high thermal stability, and provide method for forming the gel. Dispersion including: a lipid peptide type compound in which peptide portion formed by repetition of at least two or more identical or different amino acids is bonded to lipid portion including C10-24 aliphatic group; dissolution accelerator having, in molecules thereof, hydrophilic portion and hydrophobic portion, the hydrophilic portion having betaine structure; and water; and method for producing hydrogel by use of the dispersion.Type: ApplicationFiled: July 3, 2014Publication date: May 12, 2016Applicant: NISSAN CHEMICAL INDUSTRIES, LTD.Inventor: Takayuki IMOTO
-
Publication number: 20160129120Abstract: A nanocomplex containing a delivery agent and a pharmaceutical agent. The nanocomplex has a particle size of 50 to 1000 nm, the delivery agent binds to the pharmaceutical agent via non-covalent interaction or covalent bonding, and the pharmaceutical agent is a modified peptide or protein formed of a peptide or protein and an added chemical moiety that contains an anionic group, a disulfide group, a hydrophobic group, a pH responsive group, a light responsive group, a reactive oxygen species responsive group, or a combination thereof.Type: ApplicationFiled: May 13, 2014Publication date: May 12, 2016Inventors: Qiaobing XU, Ming WANG
-
Publication number: 20160129121Abstract: The present invention relates to a proteinaceous construct comprising plasmatic or recombinant factor VIIa (FVIIa) or biologically active derivatives thereof, which are bound to a carbohydrate moiety comprising 1-4 sialic acid units, wherein the in vivo half-life of the proteinaceous construct is substantially prolonged in the blood of a mammal, as compared to the in vivo half-life of a FVIIa molecule not bound to a carbohydrate moiety. The invention also provides a method for controlling bleeding in a mammal having a bleeding disorder due to functional defects or deficiencies of FVIIa, FVIII, or FIX. The invention also provides a method for controlling bleeding in a mammal during surgery or trauma.Type: ApplicationFiled: November 19, 2015Publication date: May 12, 2016Inventors: Peter Turecek, Juergen Siekmann, Friedrich Scheiflinger, Michel Canavaggio
-
Publication number: 20160129122Abstract: The invention relates to fatty acid antiviral conjugates; compositions comprising an effective amount of a fatty acid antiviral conjugate; and methods for treating or preventing a viral infection comprising the administration of an effective amount of a fatty acid antiviral conjugate.Type: ApplicationFiled: January 15, 2016Publication date: May 12, 2016Inventors: Jill C. Milne, Michael R. Jirousek, Chi B. Vu, Allison Wensley, Amal Ting
-
Publication number: 20160129123Abstract: The present invention relates to a compound which is a polysaccharide derivative of EPO, or of an EPO like protein, wherein the polysaccharide is anionic and comprises between 2 and 200 saccharide units. The present invention also relates to pharmaceutical compositions comprising the novel compounds, and methods for making the novel compounds.Type: ApplicationFiled: January 19, 2016Publication date: May 12, 2016Applicant: Lipoxen Technologies LimitedInventors: Sanjay Jain, Peter Laing, Gregory Gregoriadis, Norbert Oskar Rumpf
-
Publication number: 20160129124Abstract: The present invention relates to a compound which is a polysaccharide derivative of EPO, or of an EPO like protein, wherein the polysaccharide is anionic and comprises between 2 and 200 saccharide units. The present invention also relates to pharmaceutical compositions comprising the novel compounds, and methods for making the novel compounds.Type: ApplicationFiled: January 19, 2016Publication date: May 12, 2016Applicant: Lipoxen Technologies LimitedInventors: Sanjay Jain, Peter Laing, Gregory Gregoriadis, Norbert Oskar Rumpf
-
Publication number: 20160129125Abstract: A novel delivery system for drugs, and especially macromolecules such as proteins or oligonucleotides through biological membranes is provided, and specifically delivery of siRNA The delivery system comprises conjugation of the macromolecule drug to a moiety that enables effective passage through the membranes. Respectively, novel compounds and pharmaceutical compositions are provided, utilizing said delivery system. In one aspect of the invention, the compounds may be utilized in medical practice, for example, in delivery of siRNA or antisense oligonucleotides across biological membranes for the treatment of medical disorders.Type: ApplicationFiled: October 1, 2015Publication date: May 12, 2016Inventor: Ilan ZIV
-
Publication number: 20160129126Abstract: Disclosed herein are methods of chemical conjugation comprising contacting a lysosomal enzyme with a first crosslinking agent to introduce aldehyde groups; contacting a lysosomal targeting peptide with a second crosslinking agent to introduce a hydrazide group at the N-terminal residue; contacting the lysosomal enzyme with aldehyde groups of step a. with the lysosomal targeting peptide with a hydrazide group at the N-terminal residue of step b; and forming a lysosomal enzyme-lysosomal targeting peptide conjugate.Type: ApplicationFiled: March 14, 2014Publication date: May 12, 2016Applicant: AMICUS THERAPEUTICS, INC.Inventor: Hung DO
-
Publication number: 20160129127Abstract: This invention relates to an albumin-curcumin conjugate for application in cancer therapy, including albumin and curcumin.Type: ApplicationFiled: May 20, 2014Publication date: May 12, 2016Inventors: Lissy Kalliyana Krishnan, Christina Thomas
-
Publication number: 20160129128Abstract: Drug conjugates of formula [D-(X)b-(AA)w-(L)-]n-Ab wherein: D is a drug moiety having the following formula (I) or a pharmaceutically acceptable salt, ester, solvate, tautomer or stereoisomer thereof, wherein: A is selected from (II) and (III) R1, R2 and R3 is H, ORa, OCORa, OCO—ORa, alkyl, alkenyl, alkynyl, etc; R3? is, CORa, COORa, CONRaRb, etc; each of R4 to R10 and R12 is alkyl, alkenyl or alkynyl; R11 is H, CORa, COORa, alkyl, alkenyl or alkynyl, or R11 and R12+N+C atoms to which they are attached may form a heterocyclic group; each of R13 and R14 is H, CORa, COORa, alkyl, alkenyl or alkynyl; each Ra and Rb is H, alkyl, alkenyl, alkynyl, etc.Type: ApplicationFiled: June 2, 2014Publication date: May 12, 2016Inventors: Cármen CUEVAS MARCHANTE, Juan Manuel DOMÍNGUEZ CORREA, Andrés FRANCESCH SOLLOSO, María GARRANZO GARCÍA-IBARROLA, María José MUNOZ ALONSO, Francisco SÁNCHEZ MADRID, Juan Manuel ZAPATA HERNÁNDEZ, Alicia GARCÍA ARROYO, Maria Ángeles URSA PECHARROMÁN
-
Publication number: 20160129129Abstract: The present invention relates to a modified IgG4 Fc fragment useful as a drug carrier. When the modified IgG4 Fc fragment of the present invention is combined with an arbitrary drug, the resulting drug conjugate can minimize the effector functions of the IgG4 Fc and the chain exchange with in vivo IgG while maintaining in vivo activity and improving in vivo duration of the drug conjugate.Type: ApplicationFiled: May 29, 2014Publication date: May 12, 2016Applicant: HANMI PHARM. CO., LTD.Inventors: Sung Youb JUNG, Yong Ho HUH, Sung Hee PARK, Jong Soo LEE, In Young CHOI
-
Publication number: 20160129130Abstract: Methods for the treatment of CD30-expressing cancers are provided. The methods comprise administering to a subject in need thereof a weekly dose of from about 0.8 mg/kg to about 1.8 mg/kg of an antibody-drug conjugate compound having formula (I); or a pharmaceutically acceptable salt thereof; wherein: mAb is an anti-CD30 antibody unit, S is a sulfur atom of the antibody, A- is a Stretcher unit, and p is from about 3 to about 5.Type: ApplicationFiled: November 11, 2015Publication date: May 12, 2016Inventors: Eric Sievers, Dana Kennedy, Nathan Ihle, Michael Sun
-
Publication number: 20160129131Abstract: A system is provided which includes nanoparticle conjugates configured to bind with a tumor cell, the nanoparticle conjugate comprising a nanoparticle, at least one targeting entity bound to the nanoparticle, and at least one shielding entity that shields at the at least one targeting entity, the nanoparticle, or both; a body-mountable device mounted on an external surface of a living body and configured to detect a tumor cell binding response signal transmitted through the external surface, wherein the tumor cell binding response signal is related to binding of the nanoparticle conjugates with one or more tumor cells; and a processor configured to non-invasively detect the one or more tumor cells based on the tumor cell response signal. Nanoparticle conjugates and methods for use for treating or imaging tumor cells are also provided.Type: ApplicationFiled: November 12, 2014Publication date: May 12, 2016Inventors: Alberto Clemente VITARI, Joshua Simon KLEIN, Jerrod Joseph SCHWARTZ, Andrew HOMYK, Marija PAVLOVIC
-
Publication number: 20160129132Abstract: A process for the preparation of targeting nanoparticles of a poly(alkyl cyanoacrylate) homopolymer or copolymer, wherein said method comprises, in a single step, the anionic polymerisation of an oil-in-water miniemulsion as herein defined. The invention also relates to nanoparticles produced from said process and to their use in medicine.Type: ApplicationFiled: May 28, 2014Publication date: May 12, 2016Applicant: Sinvent ASInventors: Ruth Schmid, Per Stenstad, Yrr Morch, Heidi Johnsen
-
Publication number: 20160129133Abstract: The present invention provides compositions and methods for immunotherapy, which include shelf-stable pharmaceutical compositions for inducing antigen-specific T cells. Such compositions are employed as components of an artificial antigen presenting cell (aAPC), to provide a patient with complexes for presentation of an antigen (e.g., a tumor antigen) and/or a T cell co-stimulatory molecule.Type: ApplicationFiled: June 23, 2014Publication date: May 12, 2016Applicant: Nexlmmune, Inc.Inventors: Bruce McCreedy, Timothy David Jones, Francis Joseph Carr
-
Publication number: 20160129134Abstract: The present invention relates to a hyaluronic acid composition comprising a hyaluronic acid and one or more cyclodextrin molecules covalently bound to said hyaluronic acid via a bi- or polyfunctional crosslinking agent, wherein the covalent bonds between said hyaluronic acid and said crosslinking agent and between said crosslinking agent and said cyclodextrin molecules are ether bonds. The present invention relates to medical and cosmetic (non-medical) uses of such compositions further comprising a pharmaceutical or medical agent and to a method of preparing a slow release formulation.Type: ApplicationFiled: June 9, 2014Publication date: May 12, 2016Applicant: Galderma S.A.Inventor: Jean-Guy BOITEAU
-
Publication number: 20160129135Abstract: Embodiments of the invention are directed methods that include a thymidine kinase deficient vaccinia virus. The methods include administering the vaccinia virus at increased viral concentrations. Further aspects of the invention include methods for inducing oncolysis or collapse of tumor vasculature in a subject having a tumor comprising administering to a subject at least 1×108 infectious viral particles of a TK-deficient, GM-CSF-expressing, replication-competent vaccinia virus vector sufficient to induce oncolysis of cells in the tumor.Type: ApplicationFiled: December 11, 2015Publication date: May 12, 2016Applicant: SILLAJEN BIOTHERAPEUTICS, INC.Inventor: David Kirn
-
Publication number: 20160129136Abstract: Compositions comprising one or more nanoparticles, wherein the nanoparticles encapsulate fluorescence dyes are disclosed. In one embodiment, the nanoparticle comprises triterpene. In another embodiment, the nanoparticle comprises triterpene and fatty ester. Methods for performing a diagnostic or a therapeutic procedure comprising administering to a subject an effective amount of the compositions of the present invention or carbocyanine dyes are also provided.Type: ApplicationFiled: November 4, 2015Publication date: May 12, 2016Inventors: Chia-Yu Fang, Chih-Jen Wen
-
Publication number: 20160129137Abstract: A recombinant bacterium for detecting aged tissues and a method of detecting aged tissues in a subject, and a composition for delivering a drug to aged tissues are provided.Type: ApplicationFiled: November 6, 2015Publication date: May 12, 2016Inventors: Byounggon Moon, Hyon E. Choy, Sungchun Cho, Sangchul Park, Jaeho Jeong
-
Publication number: 20160129138Abstract: Disclosed are nanoparticles comprising octapod iron oxide having eight trigonal bipyramidal arms and a method of preparing the same. The nanoparticles are prepared by heating a mixture of a ferric carboxylate, a carboxylic acid, a chloride salt, water, and a non-polar solvent, to a temperature above about 300° C. Also disclosed is a method of magnetic resonance imaging a tissue in a mammal, comprising use of the aforesaid nanoparticles.Type: ApplicationFiled: June 3, 2013Publication date: May 12, 2016Applicants: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERV, XIAMEN UNIVERSITYInventors: Jinhao Gao, Xiaoyuan Chen, Zenghuan Zhao
-
Publication number: 20160129139Abstract: The present invention relates to a method for purification of 18F-labeled choline analogues in a solution injectable to a patient, prepared using non-gaseous synthesis paths, comprising a step of solid phase extraction (SPE) purification using a solid support, wherein the solid support used in the solid phase extraction purification has the characteristic to retain impurities and reagents from the solution but not the 18F-labeled choline analogues.Type: ApplicationFiled: June 2, 2014Publication date: May 12, 2016Inventors: Jean-Luc Morelle, Muhammad Otabashi, Gauthier Philippart, Samuel Voccia
-
Publication number: 20160129140Abstract: Described herein are compositions and methods of use of radionuclide-antibody conjugates (for RAIT) and drug-antibody conjugates (ADC). The combination of RAIT and ADC was more efficacious than either RAIT alone, ADC alone, or the sum of effects of RAIT and ADC. The unexpected synergy resulted in decreased tumor growth rate and increased survival, with a high incidence of tumor-free survival in Capan-1 human pancreatic cancer xenografts in nude mice.Type: ApplicationFiled: January 21, 2016Publication date: May 12, 2016Inventors: Serengulam V. Govindan, David M. Goldenberg
-
Publication number: 20160129141Abstract: A decontamination device for medical material, including a support intended to receive and hold said medical material to be decontaminated on a predefined axis, a spraying means, a drying means and an irradiating means, wherein said spraying means is mounted in rotation about said predefined axis and in translation parallel to said predefined axis, in such a way that the spraying is directed towards said predefined axis, said drying means is mounted in translation parallel to said predefined axis, and said irradiating means is mounted in translation parallel to said predefined axis.Type: ApplicationFiled: June 10, 2014Publication date: May 12, 2016Applicant: L.B.A. CONSULTINGInventors: Christophe BARREAU, Eric BERTRAND, Philippe MACAIRE, Jean-Paul CARPRIEAUX
-
Publication number: 20160129142Abstract: Disclosed is a system for reducing germs by means of plasma. To this end, a piezoelectric transformer is associated with a dielectric film. The peripheral edge of the dielectric film encloses an area to be sterilized, a cavity being formed thereby. A high-voltage end of the piezoelectric transformer is facing a side of the dielectric film facing away from the cavity. The plasma is ignited within the cavity.Type: ApplicationFiled: January 15, 2016Publication date: May 12, 2016Inventor: Stefan Nettesheim
-
Publication number: 20160129143Abstract: A odor elimination system includes a pad that may be positioned on a support surface and a carpet is positioned on the pad. An injection unit is provided and the injection unit contains a fluid odor eliminator. The injection unit includes a plurality of needles. The needles penetrate the carpet and the pad. Thus, the injection unit may deliver the fluid odor eliminator into the pad thereby facilitating the fluid odor eliminator to eliminate an odor associated with a contaminant in the carpet and the pad.Type: ApplicationFiled: October 30, 2015Publication date: May 12, 2016Inventor: Leisa Lingwall
-
Publication number: 20160129144Abstract: A malodor control composition having a mixture of volatile aldehydes and methods thereof are provided. The composition is suitable for a variety of applications, including use in fabric and air freshening products.Type: ApplicationFiled: January 15, 2016Publication date: May 12, 2016Inventors: Ricky Ah-Man WOO, Christine Marie READNOUR, Jason John OLCHOVY, Michael-Vincent Nario MALANYAON, Zaiyou LIU, Rhonda Jean JACKSON
-
Publication number: 20160129145Abstract: A method of neutralizing malodors by providing a malodor control composition having a mixture of volatile aldehydes is provided. In some embodiments, the malodor control composition includes an acid catalyst.Type: ApplicationFiled: January 15, 2016Publication date: May 12, 2016Inventors: Ricky Ah-Man WOO, Steven Anthony HORENZIAK, Rhonda Jean JACKSON, Zaiyou LIU, Michael-Vincent Nario MALANYAON, Jason John OLCHOVY, Christine Marie READNOUR
-
Publication number: 20160129146Abstract: The device for diffusing volatile substances, comprising a casing (1) wherein at least two respective volatile substance containers (2) are housed, said containers (2) being moveable relative to said casing (1) between at least one first position, where one of the containers (2) is exposed to the environment for diffusing its volatile substances, and a second position, where another container (2) is exposed to the environment, and characterised in that between said casing (1) and the container or containers (2) unexposed to the environment a space (3) is defined, which allows the diffusion of volatile substances from the unexposed container or containers (2) to a lesser extent than the container (2) exposed to the environment. It enables performance to be improved due to the fact that two or more fragrances in two or more containers contribute to the final performance and intensity.Type: ApplicationFiled: March 31, 2014Publication date: May 12, 2016Inventors: Montserrat Riera Giner, Ruben Garcia Fabregas, Elisabeth Martinez de Morentin Pujabet, Cedric Gobber
-
Publication number: 20160129147Abstract: The present invention provides a spill-resistant air freshener canister that includes: a supply vessel filled with aromatic liquid that has a threaded mouth sealed with a puncturable foil/polyethylene membrane; a cylindrical inner sleeve incorporating a socket that sealably engages the threaded mouth of the supply vessel, the sleeve also having a cylindrical axial aperture at the bottom of the socket, and at least one seepage aperture at the very bottom of the socket which enables liquid from inside the supply vessel to escape in a radially outward direction to the exterior of the inner cylindrical sleeve; a cylindrical wick surrounding the cylindrical inner sleeve; and an evaporator cage into which the cylindrical inner sleeve is inserted, the evaporator cage having a fully-enclosed bottom portion containing a central projecting blade that fits through the axial aperture at the bottom of the socket. The bottom portion is ultrasonically welded to the bottom of the cylindrical inner sleeve.Type: ApplicationFiled: January 19, 2016Publication date: May 12, 2016Inventor: Rami Sidawi
-
Publication number: 20160129148Abstract: The present invention relates to a method for coating polymethylmethacrylate (PMMA)-based co-polymer beads with nano-calcium phosphate. The method includes synthesizing the PMMA-based co-polymer beads containing hydroxyl pendant group, reacting the calcium salt and phosphate solution with the hydroxyl pendant group on the PMMA-based co-polymer beads, and thickening of the nano-calcium phosphate coating on the PMMA-based co-polymer beads.Type: ApplicationFiled: November 5, 2015Publication date: May 12, 2016Inventors: Chi Tak WONG, Sau Kuen Connie Kwok
-
Publication number: 20160129149Abstract: Biologically compatible polymers carry an imide and can be used as an adhesive, a hydrogel or both. A second biologically compatible polymer reactive with the imidated polymer can be used therewith to seal openings.Type: ApplicationFiled: January 5, 2016Publication date: May 12, 2016Inventors: Jennifer H. Elisseeff, Iossif A. Strehin, Xiaokun Wang
-
Publication number: 20160129150Abstract: The object of the present invention is to provide a sugar chain-polypeptide complex that may form a transparent and homogeneous hydrogel in a broad pH. The present invention provides a sugar chain-polypeptide complex, characterized in that said polypeptide is a polypeptide comprising an amino acid sequence consisting of 8-34 amino acid residues in which polar and nonpolar amino acid residues are alternately arranged, and one or more sugar chains are bound to said polypeptide.Type: ApplicationFiled: March 21, 2014Publication date: May 12, 2016Inventors: Hayato Saijo, Hirofumi Ochiai, Keisuke Tazuru, Taiji Shimoda
-
Publication number: 20160129151Abstract: Gels and films can be formed from protein dissolved into a benign solvent that comprises alcohol, water, and salt. In one example, the protein can be collagen. In one example, the benign solvent can include a water to alcohol ratio of between ninety-nine-to-one and one-to-ninety-nine by volume, a salt concentration between zero moles per liter and the maximum salt concentration soluble in water, and a protein amount of between near zero percent and about 25 percent by weight as compared to the mixture of water and alcohol. Once the protein is dissolved in the benign solvent, secondary processing steps can be conducted to form protein based bioadhesives, gels, and films with desirable physical properties. Additional process steps can include washings that improve the properties of the protein structures.Type: ApplicationFiled: November 6, 2014Publication date: May 12, 2016Inventors: Matthew J. Fullana, Daniel J. Brannum, Gary E. Wnek
-
Publication number: 20160129152Abstract: Embodiments of the present invention provides bone graft compositions, and methods for their use and manufacture. A bone graft composition may include a first amount of non-demineralized cancellous bone. The composition may further include a second amount of demineralized cancellous bone. The composition may also include a third amount of demineralized cortical bone. The non-demineralized cancellous bone, the demineralized cancellous bone, and the demineralized cortical bone may be obtained from the same cadaveric donor.Type: ApplicationFiled: January 15, 2016Publication date: May 12, 2016Inventor: Yaling Shi
-
Publication number: 20160129153Abstract: The present invention is directed to methods of manufacturing bioactive gels from ECM material, i.e., gels which retain bioactivity, and can serve as scaffolds for preclinical and clinical tissue engineering and regenerative medicine approaches to tissue reconstruction. The manufacturing methods take advantage of a new recognition that bioactive gels from ECM material can be created by digesting particularized ECM material in an alkaline environment and neutralizing to provide bioactive gels.Type: ApplicationFiled: December 15, 2015Publication date: May 12, 2016Inventors: Kimberly A. Kentner, Katherine A. Stuart, Abram D. Janis
-
Publication number: 20160129154Abstract: The invention relates to a preserved amniotic membrane, in particular a vacuum-dried amniotic membrane. It also relates to uses of vacuum-dried amniotic membrane and methods for making a vacuum-dried amniotic membrane. A method of processing an amniotic membrane to provide a vacuum-dried amniotic membrane,comprising the step of vacuum-drying the amniotic membrane Amniotic membrane (AM) is the inner most extraembryonic membrane that surrounds the foetus in a sac of amniotic fluid, functioning as a protective barrier to ascending infection and trauma during pregnancy.Type: ApplicationFiled: June 4, 2014Publication date: May 12, 2016Applicant: THE UNIVERSITY OF NOTTINGHAMInventors: Andrew HOPKINSON, Matthew BRANCH, Harminder DUA, Claire ALLEN
-
Publication number: 20160129155Abstract: Described herein are methods of fabricating human cell-based engineered musculoskeletal tissues (hCEMTs) using three dimensional fabrication technology that involves injectable materials with in situ polymerization/solidification capability and/or solid free-form fabrication. Also described is the usage of hCEMTs for tissue repair and drug testing.Type: ApplicationFiled: November 6, 2015Publication date: May 12, 2016Applicant: University of Pittsburgh - Of the Commonwealth System of Higher EducationInventors: Hang Lin, Rocky Sung Chi Tuan
-
Publication number: 20160129156Abstract: Methods and apparatus of providing a joint replacement parts with a pharmaceutical delivery system is provided. The pharmaceutical delivery system is placed within the joint replacement parts to provide, over a period of time, sustained release of a controlled concentration of pharmaceuticals within the joint space of the joint replacement and to produce a local or systemic physiological of pharmacological effect.Type: ApplicationFiled: November 8, 2014Publication date: May 12, 2016Inventors: Abraham Lin, Steve Li
-
Publication number: 20160129157Abstract: In one aspect, the invention provides an implantable device comprising a uniform mixture of components including degradable polymer, inorganic bone particulate either natural or synthetic, a drug, and a soluble microporagen. In some embodiments, the uniform mixture further includes a soluble polymer macroporagen. In some embodiments, the uniform mixture is coated with an immobilized outer porous layer comprising or consisting of synthetic or natural inorganic bone granules. In further aspects, the invention provides an implantable device comprising a composite core of degradable polymer, bone, and a drug, and a coating comprising or consisting of microporous bone overlayer covering the degradable composite core.Type: ApplicationFiled: February 5, 2014Publication date: May 12, 2016Inventors: Amanda Brooks, David Grainger, Kristofer D. Sinclair, Benjamin Brooks
-
Publication number: 20160129158Abstract: An expandable medical balloon including an inner layer formed of a poly (ether-block-amide) copolymer and an outer layer formed of a polyamide, the expandable medical balloon having a burst strength of greater than 50,000 psi, and to methods of making and using the same.Type: ApplicationFiled: January 19, 2016Publication date: May 12, 2016Applicant: BOSTON SCIENTIFIC SCIMED, INC.Inventors: John J. Chen, Daniel J. Hom
-
Publication number: 20160129159Abstract: In some aspects, the present disclosure provides medical devices that comprise a composite region comprising a binding polymer portion and an oriented fibrous polymer reinforcement portion, wherein the composite region is formed by a process that comprises heating and compressing one or more oriented polymer fibers. Other aspects of the present disclosure relative to methods of forming such medical devices.Type: ApplicationFiled: November 9, 2015Publication date: May 12, 2016Applicant: Boston Scientific Scimed, Inc.Inventors: Mark W. Bowden, Partrick Mather